Furthermore, function experiments revealed that a higher expression of FEZF1-AS1 leads to increased cell proliferation, migration, and invasiveness.[5] These previous studies indicate plasma FEZF1-AS1 as a potential novel biomarker for NSCLC diagnosis. Here, FEZF1 is linked to non-small cell lung carcinoma.